Edgestream Partners L.P. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Edgestream Partners L.P. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 141.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 219,329 shares of the biopharmaceutical company's stock after buying an additional 128,372 shares during the period. Edgestream Partners L.P. owned approximately 0.13% of ACADIA Pharmaceuticals worth $3,373,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ACAD. Fred Alger Management LLC grew its stake in ACADIA Pharmaceuticals by 17.8% during the third quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company's stock worth $49,007,000 after buying an additional 481,950 shares in the last quarter. Millennium Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 36.2% during the 2nd quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company's stock worth $47,738,000 after acquiring an additional 781,070 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in ACADIA Pharmaceuticals by 11.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 2,934,926 shares of the biopharmaceutical company's stock valued at $47,693,000 after acquiring an additional 292,906 shares during the last quarter. Marshall Wace LLP raised its position in ACADIA Pharmaceuticals by 431.1% during the second quarter. Marshall Wace LLP now owns 2,774,353 shares of the biopharmaceutical company's stock valued at $45,083,000 after purchasing an additional 2,251,940 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its stake in ACADIA Pharmaceuticals by 19.5% during the third quarter. Rockefeller Capital Management L.P. now owns 1,139,934 shares of the biopharmaceutical company's stock worth $17,532,000 after purchasing an additional 185,684 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Stock Up 1.8 %

ACADIA Pharmaceuticals stock traded up $0.29 during trading hours on Monday, reaching $16.61. 1,418,012 shares of the company's stock were exchanged, compared to its average volume of 1,664,788. The firm has a market capitalization of $2.76 billion, a PE ratio of 20.69 and a beta of 0.38. The firm's 50 day simple moving average is $15.61 and its 200 day simple moving average is $16.01. ACADIA Pharmaceuticals Inc. has a twelve month low of $14.15 and a twelve month high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The company's revenue was up 18.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.40) earnings per share. Analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.73 EPS for the current year.

Insiders Place Their Bets

In related news, insider James Kihara sold 4,073 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares in the company, valued at approximately $333,897.03. This represents a 17.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Mark C. Schneyer sold 10,259 shares of the firm's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $172,453.79. Following the transaction, the chief financial officer now owns 53,302 shares in the company, valued at approximately $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,661 shares of company stock worth $414,551. 28.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Morgan Stanley cut ACADIA Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $28.00 to $20.00 in a report on Wednesday, August 7th. Raymond James reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. UBS Group dropped their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, August 8th. Finally, Royal Bank of Canada decreased their target price on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.56.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.